Analyzing ELF Test for Early Detection of Fatty Liver in High-Risk Patients
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
This study is testing if a new liver test can help find early signs of fatty liver disease in people at high risk, like those with metabolic syndrome, and see how lifestyle changes or medications affect their liver health over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT06225193 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze enhanced liver fibrosis (ELF) scores in a high-risk population for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The study focuses on patients with metabolic syndrome and other risk factors, comparing ELF scores with traditional fibrosis assessment methods. It will also evaluate the impact of lifestyle changes and pharmacotherapy on ELF scores over time. The goal is to provide a non-invasive and cost-effective means of detecting liver fibrosis and predicting liver-related events in primary care settings.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with risk factors for NAFLD/NASH who have undergone ELF score assessment at Methodist Dallas Medical Center.
Not a fit: Patients with incomplete data or those lost to follow-up will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of fatty liver disease in high-risk patients.
How similar studies have performed: While the ELF test is a newer approach, similar studies have shown promise in using non-invasive methods for liver fibrosis assessment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: ≥ 18 years * NAFLD/NASH and non-NAFLD/NASH patients who have had an assessment with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023. Exclusion Criteria: * Patients with incomplete data and those lost to follow up.
Where this trial is running
Dallas, Texas
- Methodist Dallas Medical Center — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Parvez Mantry, MD — Methodist Midlothian Medical Center
- Study coordinator: Crystee Cooper
- Email: crysteecooper@mhd.com
- Phone: 2149471280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.